Overview

This trial is active, not recruiting.

Conditions astrocytoma, oligoastrocytoma, oligodendroglioma
Sponsor Ludwig-Maximilians - University of Munich
Collaborator Deutsche Krebshilfe e.V., Bonn (Germany)
Start date June 2008
End date December 2015
Trial size 38 participants
Trial identifier NCT01089244, GGN-CP4

Summary

The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients with a suspected WHO II low grade glioma, disease progression within 1 year
Patients with a suspected WHO II low grade glioma, progression free within 1 year

Primary Outcomes

Measure
Overall survival
time frame: 24 months

Secondary Outcomes

Measure
Progression Free survival
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II) - histological verification will be obtained either by microsurgery or by stereotactic biopsy - patients older than 18 years - Karnofsky Performance Score >=70 - pregnant or nursing female patients will not be included in this study Exclusion Criteria: - patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills - patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan - medical history of a metastatic brain disease - patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.

Additional Information

Official title Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas
Principal investigator Joerg C. Tonn, Prof. Dr.
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich.